Progression of cardiac valve calcification and decline of renal function in CKD patients

Journal of Nephrology

Volumn 26, Issue 4, 2013, Pages 739-744

  Di Lullo, Luca ^a   Floccari, Fulvio ^b   Santoboni, Alberto ^a   Barbera, Vincenzo ^a   Rivera, Rodolfo Fernando ^c   Granata, Antonio ^d   Morrone, Luigi ^e   Russo, Domenico ^f  

^a Nephrology and Dialysis Unit   (Italy)

^b San Paolo General Hospital   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

^d S Giovanni di Dio Hospital   (Italy)

^e G RUMMO HOSPITAL   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Aortic valve; C reactive protein; Calcification; FGF 23; Mitral valve; Phosphate binder; Renal function decline

Indexed keywords

C REACTIVE PROTEIN; CALCIUM; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER;

ADULT; AORTA VALVE CALCIFICATION; ARTICLE; BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONSTIPATION; DISEASE COURSE; DRUG TOLERABILITY; DYSPEPSIA; ECHOCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MITRAL VALVE CALCIFICATION; OBSERVATIONAL STUDY; OUTPATIENT; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; URINARY EXCRETION; VALVULAR HEART DISEASE;

CALCINOSIS; DISEASE PROGRESSION; FEMALE; HEART VALVE DISEASES; HUMANS; KIDNEY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84880093453     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000290     Document Type: Article

References (29)

1. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2008;19(2): 213-216.
2. Ossareh S. Vascular calcification in chronic kidney disease: mechanisms and clinical implications. Iran J Kidney Dis. 2011;5(5):285-299.
3. Moe S, Drüeke T, Cunningham J, et al. Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945-1953.
4. Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004;15(11):2857-2867.
5. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int. 2004;66(6):2293-2299.
6. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68(4):1815-1824.
7. Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62(1):245-252.
8. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71(5):438-441.
9. Isakova T, Gutiérrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009;20(2):388-396.
10. Raggi P, Vukicevic S, Moysés RM, Wesseling K, Spiegel DM. Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin J Am Soc Nephrol. 2010;5(Suppl 1):31-40.
11. Fliser D, Kollerits B, Neyer U, et al. MMKD Study Group. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007;18(9):2600-2608.
12. Russo D, Battaglia Y. Clinical significance of FGF-23 in patients with CKD. Int J Nephrol. 2011;364890:5.
13. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520-528.
14. Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007;167(9):879-885.
15. Tomiyama C, Higa A, Dalboni MA, et al. The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. Nephrol Dial Transplant. 2006;21(9):2464-2471.
16. Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007;72(10):1255-1261.
17. Di Iorio B, Bellasi A, Russo D; INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012;7(3):487-493.
18. Declerck G, Bousquet C, Jaulent MC. Automatic generation of MedDRA terms groupings using an ontology. Stud Health Technol Inform. 2012;180:73-77.
19. Amin N. The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure. Nephrol Dial Transplant. 2002;17(2):340-345.
20. Nagano N, Miyata S, Obana S, et al. Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant. 2003;18(10):2014-2023.
21. Chertow GM, Raggi P, McCarthy JT, et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol. 2003;23(5):307-314.
22. Brandenburg VM, Schlieper G, Heussen N, et al. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant. 2010;25(8):2672-2679.
23. Koiwa F, Kazama JJ, Tokumoto A, et al. ROD21 Clinical Research Group. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial. 2005;9(4):336-339.
24. Yilmaz MI, Sonmez A, Saglam M, et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis. 2012;59(2):177-185.
25. Bellizzi V, Di Iorio BR, De Nicola L, et al. ERIKA Study Group. Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease. Kidney Int. 2007;71(3):245-251.
26. Kalantar-Zadeh K, Gutekunst L, Mehrotra R, et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(3):519-530.
27. Di Iorio B, Di Micco L, Torraca S, et al. Acute effects of verylow-protein diet on FGF23 levels: a randomized study. Clin J Am Soc Nephrol. 2012;7(4):581-587.
28. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4)(Suppl 3):S1-S201.
29. Kestenbaum BR, Adeney KL, de Boer IH, Ix JH, Shlipak MG, Siscovick DS. Incidence and progression of coronary calcification in chronic kidney disease: the Multi-Ethnic Study of Atherosclerosis. Kidney Int. 2009;76(9):991-998.